Medioresinol(Medioresinol) - 药物靶点：PGC-1α_在研适应症：缺血性卒中_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MDN、Medioresinol

靶点

PGC-1α

作用方式

激动剂

作用机制

PGC-1α agonists(Peroxisome proliferator-activated receptor gamma coactivator 1-alpha agonists)

治疗领域

神经系统疾病心血管疾病

在研适应症

缺血性卒中

非在研适应症-

原研机构

中国药科大学

在研机构

中国药科大学

非在研机构-

权益机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

结构/序列

分子式C21H24O7

InChIKeyVJOBNGRIBLNUKN-BMHXQBNDSA-N

CAS号40957-99-1

关联

100 项与 Medioresinol 相关的临床结果

登录后查看更多信息

100 项与 Medioresinol 相关的转化医学

登录后查看更多信息

100 项与 Medioresinol 相关的专利（医药）

登录后查看更多信息

414

项与 Medioresinol 相关的文献（医药）

2025-06-09·VETERINARY SURGERY

Saline-based modified del Nido cardioplegia versus multidose St. Thomas cardioplegia in canine mitral valve repair: A randomized controlled trial.

Article

作者: Chen, Ayaka ; Uechi, Masami ; Sugiya, Hiroshi ; Nishiyama, Masako ; Nii, Yasuyuki ; Furusato, Shimon ; Kurogochi, Kentaro ; Takahashi, Arane

OBJECTIVE:

To compare the utility of a saline-based modified del Nido (mDN) cardioplegia solution with a conventional institutional technique (multidose St. Thomas blood cardioplegia) for mitral valve repair (MVR) in dogs.

STUDY DESIGN:

Prospective, randomized, open-label trial.

ANIMALS:

Forty client-owned dogs with myxomatous mitral valve disease (stage B2 and C) eligible for MVR were divided into control and modified mDN groups.

METHODS:

Cardioplegia was induced in the control group using 50% blood containing St. Thomas solution every 10 min. In the mDN group, a cardioplegia solution containing 20% blood was administered once or when required. As the primary outcome, serum cardiac troponin I levels were compared 12 h postoperatively between the groups. The other clinical findings were evaluated as secondary outcomes.

RESULTS:

Troponin levels 12 h after surgery were a median of 27.8 ng/mL (interquartile range, 15.1-43.2) in the control group and 19.4 ng/mL (15.2-33.6) in the mDN group (p = .478). The sinus rhythm recovery time following aortic cross-clamp removal was 362 s (103-995) in the control group and 60 s (44-605) in the mDN group (p = .027). The total amount of crystalloid cardioplegia solution required was 12.6 mL/kg (11.3-15.0) in the control group and 23.6 mL/kg (18.0-35.1) in the mDN group (p < .001).

CONCLUSION:

Cardiac troponin I levels did not show differences between the groups. The saline-based mDN cardioplegia facilitated earlier sinus rhythm recovery.

CLINICAL SIGNIFICANCE:

Saline-based mDN cardioplegia may be a viable alternative for canine MVR.

2025-06-01·BIOCHEMICAL SYSTEMATICS AND ECOLOGY

Phytochemical study of the stems of Blachia siamensis (Euphorbiaceae)

作者: Mao, Haoyu ; Zhang, Yanyan ; Duan, Xiaoxiao ; Yang, Changshui ; Cao, Yinxue ; Wang, Hengjun ; Wang, Jialin ; Dong, Xiaoyun

In the examination of the stem of Blachia siamensis, 13 compounds were isolated, including 8 phenylpropanoids and 5 phenolic acids.To elucidate their chem. structures, techniques including NMR, spectral anal., and literature comparison were utilized.This study represents the first comprehensive investigation into the constituents of B. siamensis and also explores its the correlation between chem. classification and morphol. classification.

2025-05-03·Natural product research

Molecular properties, structure and chiral resolution of secondary metabolites from the leaves of Viburnum chingii

Article

作者: Xu, Zhi-Yong ; Liang, Jing-Jing ; La, Chang-Sheng ; Huang, Xiao-Xiao ; Lv, Tian-Ming

A chemical investigation of leaves of Viburnum chingii afforded eleven compounds, including one undescribed lignan (1), a pair of known phenylpropanoid enantiomers (2a/2b), and eight known lignans (3-10). Their structures were elucidated by detailed spectroscopic and comparative literature data analysis. The absolute configurations of compounds 1 was determined by comparing the experimental ECD data with the calculated values. The compounds 2a/2b were separated successfully by a chiral chromatographic column. In addition, the acetylcholinesterase (AChE) inhibitory activities of described compounds were evaluated.

100 项与 Medioresinol 相关的药物交易

登录后查看更多信息